RecruitingPhase 2NCT06649695
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Sponsor
European Myeloma Network B.V.
Enrollment
30 participants
Start Date
Jul 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Teclistamab for people with al amyloidosis. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTeclistamab
Teclistamab will be administered via a subcutaneous injection (SC)
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06649695
Related Trials
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
NCT076386831 location
The Norwegian Immunotherapy in Multiple Myeloma Study
NCT0685512123 locations
Hungarian National Systemic Amyloidosis Registry
NCT0768933112 locations
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT061929797 locations
Evaluation of Skin Tests in Biotherapy Allergies
NCT069718481 location